Organon & Co. Long-Term Debt, Maturity, after Year Five
Organon & Co. (OGN) had Long-Term Debt, Maturity, after Year Five of $5.07 billion as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2026-02-24
- 2025-12-31: Long-Term Debt, Maturity, after Year Five $5.07B.
- 2024-12-31: Long-Term Debt, Maturity, after Year Five $5.42B.
- 2023-12-31: Long-Term Debt, Maturity, after Year Five $2.00B.
- 2023-09-30: Long-Term Debt, Maturity, after Year Five $8.70B.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2025-12-31 | $5.07B 10-K · filed 2026-02-24 |
| 2024-12-31 | $5.42B 10-K/A · filed 2025-11-10 |
| 2023-12-31 | $2.00B 10-K · filed 2024-02-26 |
| 2023-09-30 | $8.70B 10-Q · filed 2023-11-03 |
| 2023-06-30 | $8.78B 10-Q · filed 2023-08-09 |
| 2023-03-31 | $8.77B 10-Q · filed 2023-05-05 |
| 2022-12-31 | $8.97B 10-K · filed 2023-02-27 |
| 2021-12-31 | $9.15B 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |